Compare · CRNX vs LJPC
CRNX vs LJPC
Side-by-side comparison of Crinetics Pharmaceuticals Inc. (CRNX) and La Jolla Pharmaceutical Company (LJPC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. CRNX focuses on Biotechnology: Pharmaceutical Preparations, while LJPC focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- CRNX is the larger of the two at $8.80B, about 73.4x LJPC ($120.0M).
- CRNX has hit the wire 19 times in the past 4 weeks while LJPC has been quiet.
- CRNX has more recent analyst coverage (18 ratings vs 0 for LJPC).
- Company
- Crinetics Pharmaceuticals Inc.
- La Jolla Pharmaceutical Company
- Price
- $83.45-0.10%
- $6.22+0.24%
- Market cap
- $8.80B
- $120.0M
- 1M return
- +153.45%
- -
- 1Y return
- +184.04%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 1994
- News (4w)
- 19
- 0
- Recent ratings
- 18
- 0
Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist that has completed phase II clinical trial for the treatment of acromegaly, as well as completed phase 1 clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist to treat congenital hyperinsulinism, which is in phase 1 clinical trial; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase 1 clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.
La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company was incorporated in 1989 and is headquartered in San Diego, California.
Latest CRNX
- Director Vivaldi Coelho Rogerio sold $120,000 worth of shares (3,000 units at $40.00) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 19,225 units (SEC Form 4)
- SEC Form DEFA14A filed by Crinetics Pharmaceuticals Inc.
- SEC Form DEFA14A filed by Crinetics Pharmaceuticals Inc.
- SEC Form 8-K filed by Crinetics Pharmaceuticals Inc.
- Vertex to Acquire Crinetics Pharmaceuticals
- SEC Form 144 filed by Crinetics Pharmaceuticals Inc.
- UBS initiated coverage on Crinetics Pharmaceuticals with a new price target
- Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026
- Director Deardorf Caren was granted 5,925 shares, increasing direct ownership by 36% to 22,225 units (SEC Form 4)
- Director Fust Matthew K was granted 5,925 shares, increasing direct ownership by 26% to 28,761 units (SEC Form 4)
Latest LJPC
- SEC Form 15-12G filed by La Jolla Pharmaceutical Company
- SEC Form SC 13D/A filed by La Jolla Pharmaceutical Company (Amendment)
- SEC Form SC 13D filed by La Jolla Pharmaceutical Company
- SEC Form 4 filed by Rosen Robert
- SEC Form 4: Ramsay David A returned $623,000 worth of shares to the company (100,000 units at $6.23), closing all direct ownership in the company
- SEC Form 4 filed by Tang Kevin C
- SEC Form 4: Edwards Larry G. returned $74,567 worth of shares to the company (11,969 units at $6.23), closing all direct ownership in the company
- SEC Form 4 filed by Hearne Michael S
- SEC Form 4: Johnson Laura L. returned $3,115 worth of shares to the company (500 units at $6.23), closing all direct ownership in the company
- SEC Form 4: Johnson Craig A returned $74,760 worth of shares to the company (12,000 units at $6.23), closing all direct ownership in the company